SCHEMBL7704948

SCHEMBL7704948

COc1ccc(CC(NC(=O)OC(C)(C)C)c2ccc3c(c2)N=C(N)C(C)O3)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.40
ALDH1A1 P00352 4/20 0.38
NPSR1 Q6W5P4 3/20 0.38
MAPT P10636 2/20 0.38
LMNA P02545 2/20 0.38
PKM P14618 2/20 0.38
HPGD P15428 2/20 0.38
TSHR P16473 2/20 0.38
HTT P42858 2/20 0.38
HSD17B10 Q99714 2/20 0.38
TP53 P04637 1/20 0.38
AGTR1 P30556 1/20 0.38
RAB9A P51151 1/20 0.38
PPARG P37231 1/20 0.37
PPARA Q07869 1/20 0.37
CACNA1B Q00975 2/20 0.36
MEN1 O00255 4/20 0.36
KMT2A Q03164 4/20 0.36
POLB P06746 1/20 0.36
ALOX15 P16050 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7711369 0.92 ALDH1A1 (0.37) SMN1; SMN2ALDH1A1NPSR1MAPTLMNA
SCHEMBL7704877 0.92 CACNA1B (0.40) SMN1; SMN2ALDH1A1NPSR1MAPTLMNA
SCHEMBL7708193 0.91 ALDH1A1 (0.38) SMN1; SMN2ALDH1A1NPSR1MAPTLMNA
SCHEMBL7708356 0.90 CTSS (0.41) SMN1; SMN2ALDH1A1NPSR1MAPTLMNA
SCHEMBL7704969 0.90 ALDH1A1 (0.36) SMN1; SMN2ALDH1A1NPSR1MAPTLMNA
SCHEMBL7704912 0.90 ALDH1A1 (0.45) SMN1; SMN2ALDH1A1NPSR1MAPTLMNA
SCHEMBL7711330 0.89 CTSS (0.36) SMN1; SMN2ALDH1A1NPSR1MAPTLMNA
SCHEMBL7713438 0.88 PTPRB (0.38) SMN1; SMN2ALDH1A1NPSR1MAPTLMNA
SCHEMBL7710751 0.88 CA2 (0.41) SMN1; SMN2ALDH1A1NPSR1MAPTLMNA
SCHEMBL7708354 0.87 PPARG (0.39) SMN1; SMN2ALDH1A1NPSR1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed